APEX | Obesity Grabs the Headlines: Looking at a Novo Formulary Win and a New Paper on Budget Impact

So there won’t be news this week on the government’s opening offer** around price controls for the first 10 medicines selected under the Inflation Reduction Act. Companies will get the

The House yesterday passed a mammoth health bill -- including some of the most sweeping PBM regulations ever -- by a huge margin. It includes a ban on spread pricing

I know I said that Cost Curve would be off today, but there were three items that caught my eye yesterday that I wanted to make sure I shared before